We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

35 hedge funds and large institutions have $23.4M invested in VYNE Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

64% more capital invested

Capital invested by funds: $14.3M → $23.4M (+$9.12M)

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

6% more funds holding

Funds holding: 33 → 35 (+2)

1.93% less ownership

Funds ownership: 49.82% → 47.9% (-1.9%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
35
Holders Change
+2
Holders Change %
+6.06%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
10
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$643K
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$403K
3
Citadel Advisors
Citadel Advisors
Florida
+$113K
4
BCM
Bridgeway Capital Management
Texas
+$96.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$82.7K

Top Sellers

1
AA
AlphaCentric Advisors
Puerto Rico
-$505K
2
ACM
ADAR1 Capital Management
Texas
-$287K
3
Renaissance Technologies
Renaissance Technologies
New York
-$161K
4
SCM
Silverarc Capital Management
Massachusetts
-$144K
5
PHP
Parkman Healthcare Partners
Connecticut
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$4.67M – – –
EAM
2
Eventide Asset Management
Massachusetts
$4.45M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$4.12M +$113K +43,044 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.59M +$82.7K +31,611 +7%
ACA
5
Acorn Capital Advisors
New York
$1.53M +$1.2M +456,970 New
PAI
6
Palo Alto Investors
California
$1.49M – – –
EAM
7
Exome Asset Management
New York
$1.18M – – –
UOC
8
UBS O'Connor
Illinois
$823K +$643K +245,800 New
SSA
9
Schonfeld Strategic Advisors
New York
$592K +$21.1K +8,058 +5%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$516K +$403K +154,134 New
PHP
11
Parkman Healthcare Partners
Connecticut
$512K -$131K -50,000 -25%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$452K +$1.12K +427 +0.3%
BlackRock
13
BlackRock
New York
$279K +$641 +245 +0.3%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$237K +$27.4K +10,476 +17%
PCM
15
Prelude Capital Management
New York
$199K -$15K -5,747 -9%
BCM
16
Bridgeway Capital Management
Texas
$124K +$96.7K +36,958 New
SCA
17
STALEY CAPITAL ADVISERS
Pennsylvania
$122K – – –
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$84K +$59.6K +22,789 +934%
Renaissance Technologies
19
Renaissance Technologies
New York
$83.6K -$161K -61,700 -71%
Northern Trust
20
Northern Trust
Illinois
$80.3K -$34.9K -13,319 -36%
XT
21
XTX Topco
Cayman Islands
$70.4K +$55K +21,018 New
Jane Street
22
Jane Street
New York
$68K +$53.1K +20,286 New
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$61K – – –
State Street
24
State Street
Massachusetts
$52.8K – – –
Morgan Stanley
25
Morgan Stanley
New York
$14.4K +$6.54K +2,500 +139%
1
2

VYNE Hedge Fund Activity: Q4 2024 in Review

35 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2024, worth a combined $23.4M — up 64% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new VYNE positions and 6 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $643K. The largest seller was AlphaCentric Advisors, exiting entirely with an estimated $505K sold.

  • 35 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2024, up from 33 in Q3 2024.
  • Funds reported $23.4M of VYNE Therapeutics stock for Q4 2024, up 64% quarter-over-quarter.
  • 9 funds opened new VYNE Therapeutics positions in Q4 2024 and 6 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q4 2024 was UBS O'Connor, an estimated $643K added.
  • The largest VYNE Therapeutics seller in Q4 2024 was AlphaCentric Advisors, an estimated $505K sold.

Based on aggregated 13F filings for Q4 2024.